Literature DB >> 12429021

Histone deacetylases (HDACs): characterization of the classical HDAC family.

Annemieke J M de Ruijter1, Albert H van Gennip, Huib N Caron, Stephan Kemp, André B P van Kuilenburg.   

Abstract

Transcriptional regulation in eukaryotes occurs within a chromatin setting, and is strongly influenced by the post-translational modification of histones, the building blocks of chromatin, such as methylation, phosphorylation and acetylation. Acetylation is probably the best understood of these modifications: hyperacetylation leads to an increase in the expression of particular genes, and hypoacetylation has the opposite effect. Many studies have identified several large, multisubunit enzyme complexes that are responsible for the targeted deacetylation of histones. The aim of this review is to give a comprehensive overview of the structure, function and tissue distribution of members of the classical histone deacetylase (HDAC) family, in order to gain insight into the regulation of gene expression through HDAC activity. SAGE (serial analysis of gene expression) data show that HDACs are generally expressed in almost all tissues investigated. Surprisingly, no major differences were observed between the expression pattern in normal and malignant tissues. However, significant variation in HDAC expression was observed within tissue types. HDAC inhibitors have been shown to induce specific changes in gene expression and to influence a variety of other processes, including growth arrest, differentiation, cytotoxicity and induction of apoptosis. This challenging field has generated many fascinating results which will ultimately lead to a better understanding of the mechanism of gene transcription as a whole.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12429021      PMCID: PMC1223209          DOI: 10.1042/BJ20021321

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  124 in total

1.  Functional and physical interaction between the histone methyl transferase Suv39H1 and histone deacetylases.

Authors:  Olivier Vaute; Estelle Nicolas; Laurence Vandel; Didier Trouche
Journal:  Nucleic Acids Res       Date:  2002-01-15       Impact factor: 16.971

2.  Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR.

Authors:  Wolfgang Fischle; Franck Dequiedt; Michael J Hendzel; Matthew G Guenther; Mitchell A Lazar; Wolfgang Voelter; Eric Verdin
Journal:  Mol Cell       Date:  2002-01       Impact factor: 17.970

3.  Molecular cloning and characterization of a novel histone deacetylase HDAC10.

Authors:  Amaris R Guardiola; Tso-Pang Yao
Journal:  J Biol Chem       Date:  2001-11-28       Impact factor: 5.157

4.  Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells.

Authors:  Mitsuhiro Suenaga; Hiroshi Soda; Mikio Oka; Akihiko Yamaguchi; Katsumi Nakatomi; Ken Shiozawa; Shigeru Kawabata; Takashi Kasai; Yasuaki Yamada; Shimeru Kamihira; Chuwa Tei; Shigeru Kohno
Journal:  Int J Cancer       Date:  2002-02-10       Impact factor: 7.396

5.  Isolation and characterization of a novel class II histone deacetylase, HDAC10.

Authors:  Denise D Fischer; Richard Cai; Umesh Bhatia; Fred A M Asselbergs; Chuanzheng Song; Robert Terry; Nancy Trogani; Roland Widmer; Peter Atadja; Dalia Cohen
Journal:  J Biol Chem       Date:  2001-12-05       Impact factor: 5.157

6.  Identification of HDAC10, a novel class II human histone deacetylase containing a leucine-rich domain.

Authors:  Jenny J Tong; Jianhong Liu; Nicholas R Bertos; Xiang-Jiao Yang
Journal:  Nucleic Acids Res       Date:  2002-03-01       Impact factor: 16.971

7.  The histone deacetylase inhibitor trichostatin A derepresses the telomerase reverse transcriptase (hTERT) gene in human cells.

Authors:  Mi Hou; XiongBiao Wang; Nikita Popov; Anju Zhang; Xiaoyan Zhao; Rong Zhou; Anders Zetterberg; Magnus Björkholm; Marie Henriksson; Astrid Gruber; Dawei Xu
Journal:  Exp Cell Res       Date:  2002-03-10       Impact factor: 3.905

8.  Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells.

Authors:  Masaki Kitazono; Vemulkonda Koneti Rao; Rob Robey; Takashi Aikou; Susan Bates; Tito Fojo; Merrill E Goldsmith
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

9.  Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to response to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo.

Authors:  Da-Cheng Zhou; Soon H Kim; Wei Ding; Cynthia Schultz; Raymond P Warrell; Robert E Gallagher
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

10.  Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates.

Authors:  Stacy W Remiszewski; Lidia C Sambucetti; Peter Atadja; Kenneth W Bair; Wendy D Cornell; Michael A Green; Kobporn Lulu Howell; Manfred Jung; Paul Kwon; Nancy Trogani; Heather Walker
Journal:  J Med Chem       Date:  2002-02-14       Impact factor: 7.446

View more
  964 in total

1.  Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome.

Authors:  Alan P Kozikowski; Sida Shen; Marta Pardo; Maurício T Tavares; Dora Szarics; Veronick Benoy; Chad A Zimprich; Zsófia Kutil; Guiping Zhang; Cyril Bařinka; Matthew B Robers; Ludo Van Den Bosch; James H Eubanks; Richard S Jope
Journal:  ACS Chem Neurosci       Date:  2018-12-14       Impact factor: 4.418

2.  Selenium-containing histone deacetylase inhibitors for melanoma management.

Authors:  Raghavendra Gowda; Subbarao V Madhunapantula; Dhimant Desai; Shantu Amin; Gavin P Robertson
Journal:  Cancer Biol Ther       Date:  2012-06-06       Impact factor: 4.742

3.  Synthesis, characterization, and evaluation of Cd[L-proline]2, a novel histone deacetylase inhibitor that induces epigenetic modification of histone deacetylase isoforms in A549 cells.

Authors:  Anusha Chidambaram; Arunachalam Sekar; Kavya S H; Ramesh Kumar Chidambaram; Kalaiarasi Arunachalam; Senthilkumar G P; Ravikumar Vilwanathan
Journal:  Invest New Drugs       Date:  2017-08-03       Impact factor: 3.850

4.  Expression of Class I Histone Deacetylases in Ipsilateral and Contralateral Hemispheres after the Focal Photothrombotic Infarction in the Mouse Brain.

Authors:  Svetlana Demyanenko; Maria Neginskaya; Elena Berezhnaya
Journal:  Transl Stroke Res       Date:  2017-12-07       Impact factor: 6.829

5.  Design, synthesis and anti-tumor activity study of novel histone deacetylase inhibitors containing isatin-based caps and o-phenylenediamine-based zinc binding groups.

Authors:  Shuai Gao; Jie Zang; Qianwen Gao; Xuewu Liang; Qinge Ding; Xiaoyang Li; Wenfang Xu; C James Chou; Yingjie Zhang
Journal:  Bioorg Med Chem       Date:  2017-03-19       Impact factor: 3.641

6.  Design, synthesis, biological evaluation, and structural characterization of potent histone deacetylase inhibitors based on cyclic alpha/beta-tetrapeptide architectures.

Authors:  Ana Montero; John M Beierle; Christian A Olsen; M Reza Ghadiri
Journal:  J Am Chem Soc       Date:  2009-03-04       Impact factor: 15.419

7.  Transcription factor interactions and chromatin modifications associated with p53-mediated, developmental repression of the alpha-fetoprotein gene.

Authors:  Thi T Nguyen; Kyucheol Cho; Sabrina A Stratton; Michelle Craig Barton
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

8.  Role of Dorsal Striatum Histone Deacetylase 5 in Incubation of Methamphetamine Craving.

Authors:  Xuan Li; Maria B Carreria; Kailyn R Witonsky; Tamara Zeric; Olivia M Lofaro; Jennifer M Bossert; Jianjun Zhang; Felicia Surjono; Christopher T Richie; Brandon K Harvey; Hyeon Son; Christopher W Cowan; Eric J Nestler; Yavin Shaham
Journal:  Biol Psychiatry       Date:  2017-12-29       Impact factor: 13.382

9.  Zebrafish colgate/hdac1 functions in the non-canonical Wnt pathway during axial extension and in Wnt-independent branchiomotor neuron migration.

Authors:  Roopa M Nambiar; Myron S Ignatius; Paul D Henion
Journal:  Mech Dev       Date:  2007-07-14       Impact factor: 1.882

10.  Suppression of lipopolysaccharide- and tumour necrosis factor-alpha-induced interleukin (IL)-8 expression by glucocorticoids involves changes in IL-8 promoter acetylation.

Authors:  L G Tsaprouni; K Ito; I M Adcock; N Punchard
Journal:  Clin Exp Immunol       Date:  2007-08-17       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.